Conexiant
Login
  • The Analytical Scientist
  • The Cannabis Scientist
  • The Medicine Maker
  • The Ophthalmologist
  • The Pathologist
  • The Traditional Scientist
The Medicine Maker
  • Explore

    Explore

    • Latest
    • Features
    • Interviews
    • Business & Trends
    • Technology & Manufacturing
    • Product Profiles
    • White Papers

    Featured Topics

    • Biopharma
    • Small Molecules
    • Cell & Gene
    • Future of Pharma

    Issues

    • Latest Issue
    • Archive
    • Cell and Gene Therapy Supplement
  • Topics

    Topics

    • Drug Discovery
    • Development & Clinical
    • Formulation
    • Drug Delivery
    • Bioprocessing
    • Small Molecules
    • Cell and Gene
    • Facilities & Equipment
    • Outsourcing
    • Packaging
    • Supply Chain
    • Regulation & Standards
  • News & Blogs

    News & Blogs

    • Industry News
    • Research News
    • Blogs
  • Events
    • Live Events
    • Webinars
  • Community & Awards

    Community & Awards

    • Power List
    • Sitting Down With
    • Innovation Awards
    • Company of the Year Awards
    • Authors & Contributors
  • Multimedia
    • Video
    • Podcasts
    • eBooks
Subscribe
Subscribe
The Medicine Maker / Issues / 2019 / Articles / Sep / Of Men and Mice
Discovery & Development Clinical Trials Drug Discovery Translational Science Drug Discovery Research News

Of Men and Mice

Male animal bias in preclinical research isn’t scientifically justified and may be skewing our understanding of the brain

By James Strachan 09/16/2019 0 min read Quick Read (pre 2022)

Share

For the past half century, preclinical neuroscience researchers have almost exclusively used male animals. The result? An unclear picture of the neural mechanisms that may underlie disease susceptibility in women – according to Rebecca M. Shansky, associate professor of psychology at Northeastern University in the US.

“Males and females can metabolize drugs differently, so I think if we study only males, we can miss potential side effects that women might experience,” says Shansky. “We might also find that drugs don’t work as well in females, so it’s really important to study both.”

In her article for Science (1), Shansky explains that the imbalance is rooted in the belief that circulating ovarian hormones make data from female animals messier and more variable than data from males – a claim refuted by two recent meta analyses in mice and rats (2,3).

In 2014, the NIH and the Canadian Institutes of Health Research introduced new mandates for researchers to consider sex as an experimental variable, generating a great deal of debate in the research community. And in August, 2019, Senior Editors of the British Journal of Pharmacology followed suit by recommending that all future studies published in the journal should formally address sex as an experimental variable (4).

“I saw the field of neuroscience become concerned that ovarian hormones would complicate their research (which is why they didn’t study females in the first place),” says Shansky. “I wrote the piece to help dispel their concerns and ask them to think about why they were under the impression that hormones made data from females more variable than males when that is in fact not true.”

Shansky says the reaction has been overwhelmingly positive. “It really seemed to resonate that there were some cultural biases underlying the reasoning for not studying females,” she says. “Generally speaking, I think many researchers are coming around to using both sexes. And if they are in the US and want NIH funding, they’re going to have to be!”

Newsletters

Receive the latest analytical science news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

References

  1. RM Shansky, “Are hormones a ‘female problem’ for animal research?”, Science, 364, 825-826 (2019). PMID: 31147505.
  2. BJ Prendergast, KG Onishi and I Zucker, “Female mice liberated for inclusion in neuroscience and biomedical research”, Neurosci Biobehav Rev, 40, 1 (2014). PMID: 24456941.
  3. JB Becker, BJ Prendergast and JW Liang, “Female rats are not more variable than male rats: a meta-analysis of neuroscience studies”, Biol Sex Differ, 7, 34 (2016). PMID: 27468347.
  4. JR Docherty et al, “Sex: A change in our guidelines to authors to ensure that this is no longer an ignored experimental variable”, Br J Pharmacol [Epub ahead of print] (2019). PMID: 31441038.

About the Author(s)

James Strachan

Over the course of my Biomedical Sciences degree it dawned on me that my goal of becoming a scientist didn’t quite mesh with my lack of affinity for lab work. Thinking on my decision to pursue biology rather than English at age 15 – despite an aptitude for the latter – I realized that science writing was a way to combine what I loved with what I was good at. From there I set out to gather as much freelancing experience as I could, spending 2 years developing scientific content for International Innovation, before completing an MSc in Science Communication. After gaining invaluable experience in supporting the communications efforts of CERN and IN-PART, I joined Texere – where I am focused on producing consistently engaging, cutting-edge and innovative content for our specialist audiences around the world.

More Articles by James Strachan

False

Advertisement

Recommended

False

Related Content

The (Un)fairer Sex?
Clinical Trials
The (Un)fairer Sex?

November 6, 2014

0 min read

Our understanding of the differences in male and female biology is constantly growing – but can we translate that knowledge into better healthcare for all?

Sex Matters
Clinical Trials
Sex Matters

November 6, 2014

0 min read

New NIH policies aim to correct the sex bias in preclinical research

Asking the Right Questions in R&D
Clinical Trials Contract Development Services Trends & Forecasts
Asking the Right Questions in R&D

March 6, 2025

3 min read

And getting the right people involved from the start. Here’s why collaboration is key for successful clinical development.

AI, Big Data, and Digital Disruption
Digital Technologies Clinical Trials
AI, Big Data, and Digital Disruption

March 31, 2025

7 min read

An industry survey looks at changing attitudes and challenges in digital innovation for clinical research. Uptake is slow but steady.

The Medicine Maker
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Advertise With Us
  • Contact Us

Copyright © 2025 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.